Cost-effectiveness analysis of elacestrant versus standard endocrine therapy for second-/third-line treatment of patients with HR+/HER2- advanced or metastatic breast cancer: a US payer perspective

Cost-effectiveness analysis of elacestrant versus standard endocrine therapy for second-/third-line treatment of patients with HR+/HER2- advanced or metastatic breast cancer: a US payer perspective

BackgroundThis study evaluated the cost-effectiveness of elacestrant (ELA) and standard-of-care (SOC) as second-/third-line treatment for pretreated estrogen receptor (ER)– positive/human epidermal growth factor receptor 2 (HER2)–negative advanced or metastatic breast cancer (A/MBC) in the US.Method...

Full description

Bibliographic Details
Main Authors: Wanxian Zeng, Xueqiong Cao, Jingwen Lin, Bin Zheng, Na Li, Maobai Liu, Hongfu Cai
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-12-01
Series:Frontiers in Oncology
Subjects:
cost-effectiveness
elacestrant
partitioned survival model
advanced breast cancer
oncology
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1272586/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1272586/full

Similar Items